Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy

This publication has 19 references indexed in Scilit:

• COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
  Endocrinology, 1991
• Steroid Metabolism and Binding in Relation to Prostatic Cell Growth and Differentiation in Vitro
  Annals of the New York Academy of Sciences, 1990
• Inhibitors of steroid 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne
  Trends in Pharmacological Sciences, 1989
• Efficacy and advantages in the use of low doses of anandron and estrogen combination in the treatment of prostate cancer
  The Prostate, 1988
• The effect of 4MA, a potent inhibitor of 5 alpha‐reductase, on the growth of androgen‐responsive human genitourinary tumors grown in athymic nude mice
  The Prostate, 1987
• Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H)
  The Prostate, 1987
• Biochemical and biological studies with 4-aza-steroidal 5α-reductase inhibitors
  Journal of Steroid Biochemistry, 1983
• New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
  The Prostate, 1983
• Biological Activities of a New Steroidal Inhibitor of 4-5 -Reductase
  Experimental Biology and Medicine, 1982
• Response of Rat Ventral Prostate to a New and Novel 5αa-Reductase Inhibitor
  Endocrinology, 1981